[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607465":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":19,"locations":29,"responsibleParty":47,"collaborators":18,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":18,"eligibilityCriteria":54,"healthyVolunteers":51,"sex":55,"minAge":56,"maxAge":18,"enrollmentInfo":57,"targetDuration":18,"studyType":60,"phases":61,"briefSummary":11,"conditions":63,"keywords":18,"overallStatus":65,"whyStopped":18,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patient-Donor Derived Probiotics","EXPERIMENTAL","To clinically evaluate the efficacy of patient- and\u002For donor-derived probiotics in ameliorating intestinal flora dysbiosis in patients with acute intestinal graft-versus-host disease (aGVHD), thereby mechanistically enhancing clinical outcomes and quality of life through intestinal microbiome modulation.",[13],"Drug: Patient-Donor Derived Probiotics",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"DRUG",[9],null,[20,25],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Erlie Jiang, doctor","CONTACT","+86-15122538106","jiangerlie@ihcams.ac.cn",{"name":26,"role":22,"phone":27,"phoneExt":18,"email":28},"xin Chen","+86-13920985705","chenxin@ihcams.ac.cn",[30],{"facility":31,"status":18,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","Tianjin","Tianjin Municipality","300020","China","CN",{"type":38,"coordinates":39},"Point",[40,41],117.17667,39.14222,{"lat":41,"lon":40},[44],{"name":45,"role":22,"phone":46,"phoneExt":18,"email":24},"Erlie Jiang","+86 22 23608600",{"type":48,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100607465","clinical-observation-on-the-efficacy-of-patient-donor-derived-probiotics-in-improving-intestinal-flora-disorder-in-patients-with-intestinal-acute-graft-versus-host-disease-agvhd-100607465",false,"NCT07188909","Clinical Observation on the Efficacy of Patient-Donor Derived Probiotics in Improving Intestinal Flora Disorder in Patients With Intestinal Acute Graft-Versus-Host Disease (aGVHD)","Inclusion Criteria:\n\nSubjects eligible for this study must satisfy all of the following criteria:\n\n1. Age \\>50 years, regardless of gender;\n2. Scheduled for haploidentical hematopoietic stem cell transplantation;\n3. ECOG performance status score ≤2;\n4. Voluntarily participate and provide written informed consent.\n\nExclusion Criteria:\n\nSubjects presenting with any of the following conditions will be excluded from this study:\n\n1. Active or chronic infectious diseases, including recent febrile symptoms (axillary temperature ≥37.3°C within 48h);\n2. Gastrointestinal disorders:\n\n   * Clostridioides difficile infection (CDI): Recurrent or refractory CDI;\n   * Other conditions: Ulcerative colitis, Crohn's disease, irritable bowel syndrome (IBS), diarrhea associated with dysbiosis, liver cirrhosis;\n3. Allergic or immune-mediated diseases:\n\n   Autoimmune hepatitis, systemic lupus erythematosus (SLE), ankylosing spondylitis, immune-mediated osteoarthritis, allergic dermatitis, immune thrombocytopenic purpura (ITP);\n4. Antibiotic usage within 7 days prior to enrollment.","ALL","50 Years",{"count":58,"type":59},10,"ESTIMATED","INTERVENTIONAL",[62],"NA",[64],"Acute Graft-Versus-Host Disease","NOT_YET_RECRUITING","2025-09-16",{"date":68,"type":69},"2025-09-23","ACTUAL",{"date":71,"type":59},"2025-09-15",{"date":73,"type":59},"2026-03-04",{"name":5,"class":6},1]